References in periodicals archive ?
The proteasome inhibitor carfilzomib has taken on an increasing role in the treatment of multiple myeloma
s proteasome inhibitor, marizomib, which is in development for glioblastoma and relapsed and/or refractory multiple myeloma, Triphase said.
Ixazomib, a proteasome inhibitor, is also given in combination with lenalidomide and dexamethasone, so the concerns are the same.
Iceni Pharmaceuticals is planning a Phase II safety/efficacy trial of Cilcane starting in 2017 aimed at relapsed refractory patients who have already received one prior therapy of proteasome inhibitor.
Bortezomib, the first therapeutic proteasome inhibitor, is one of the primary agents in the treatment of multiple myeloma (MM).
The major medications used for chemotherapy include various combinations of the following agents: the immunomodulators thalidomide and lenalidomide; the proteasome inhibitor bortezomib; the alkylating agents melphalan and cyclophosphamide; and the steroids dexamethasone and prednisone.
A furan-structure has been shown to be involved in some 20S proteasome inhibitor, we next designed this study to investigate if terazosin is able to inhibit proteasome activity and if proteasome activity inhibition is one of molecule mechanisms mediate anti-cancer cell activity of terazosin.
Bortezomib is a reversible proteasome inhibitor, currently approved by US FDA for use in multiple myeloma and mantle cell lymphoma.
The multi-center study with MLN9708, an investigational, oral proteasome inhibitor, will be conducted in Europe and North America.
In July 2012, the market reached a new milestone with the approval of Onyx's Kyprolis, a proteasome inhibitor with an improved safety profile and potential to be another blockbuster.
Phase 1 trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.

Full browser ?